Shares of Tharimmune, Inc. (NASDAQ:THAR – Free Report) are scheduled to reverse split on the morning of Tuesday, May 28th. The 1-15 reverse split was announced on Tuesday, May 28th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, May 28th.
Tharimmune Price Performance
NASDAQ THAR opened at $0.30 on Friday. Tharimmune has a twelve month low of $0.30 and a twelve month high of $10.87. The company’s 50-day simple moving average is $0.39 and its 200 day simple moving average is $0.81.
Tharimmune (NASDAQ:THAR – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter.
About Tharimmune
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Stories
- Five stocks we like better than Tharimmune
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 5/20 – 5/24
- Stock Average Calculator
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- About the Markup Calculator
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
